Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

594
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
594
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

464
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
464
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

493
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
493
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

611
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
611
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

506
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
506
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

621
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
621

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolomic Network Analysis Reveals Reorganization of Lipid and Steroid Programs Linked to Right Ventricular-Pulmonary Vascular Function in Pulmonary Hypertension.

bioRxiv : the preprint server for biology·2026
Same author

Blood Pressure Change After Six-minute Walk Test Is an Independent Predictor of Clinical Worsening in Patients with Pulmonary Hypertension.

Annals of the American Thoracic Society·2026
Same author

Patient Perspectives on Palliative Care in Pulmonary Arterial Hypertension in the United States.

Pulmonary circulation·2026
Same author

Resolving Diagnostic Discordance in Group 2 Pulmonary Hypertension Through Staged Physiologic Testing: Insights From PVDOMICS.

medRxiv : the preprint server for health sciences·2026
Same author

Echocardiographic characterization of combined postcapillary and precapillary pulmonary hypertension in systemic sclerosis with preserved ejection fraction.

Echo research and practice·2026
Same author

Identification of drug candidates for rescue of SOX17 gene targets in pulmonary arterial hypertension.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jan 27, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

762

Identifying Patients with Pulmonary Arterial Hypertension Using Administrative Claims Algorithms.

Stephen C Mathai1, Anna Ryan Hemnes2, Scott Manaker3

  • 11 Johns Hopkins University School of Medicine, Baltimore, Maryland.

Annals of the American Thoracic Society
|March 14, 2019
PubMed
Summary
This summary is machine-generated.

Accurately identifying patients with pulmonary arterial hypertension (PAH) in claims databases is crucial for research. This study outlines best practices for developing algorithms to ensure reliable patient identification for real-world evidence generation.

Keywords:
administrative claimspulmonary arterial hypertensionpulmonary hypertension

More Related Videos

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

908
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.7K

Related Experiment Videos

Last Updated: Jan 27, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

762
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

908
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.7K

Area of Science:

  • Health economics and outcomes research
  • Real-world evidence generation
  • Pulmonary arterial hypertension (PAH) research

Background:

  • Retrospective claims database studies offer valuable insights into treatment patterns, healthcare resource utilization, and costs.
  • Accurate patient identification is essential for reliable real-world evidence (RWE) in pulmonary arterial hypertension (PAH).
  • Current methodologies for identifying PAH patients in administrative claims data lack standardization.

Purpose of the Study:

  • To address the need for a standardized, evidence-based approach to identify patients with pulmonary arterial hypertension (PAH) in administrative claims databases.
  • To recommend best practices for developing algorithms for PAH patient identification in claims data.
  • To support accurate RWE generation for informing policy, formulary, and regulatory decisions.

Main Methods:

  • A panel of pulmonary hypertension clinical experts and researchers convened.
  • Literature review on identifying PAH patients in claims databases was conducted.
  • Best practices for developing PAH identification algorithms were recommended.

Main Results:

  • No standardized methodology currently exists for identifying PAH patients in claims data.
  • A systematic approach is needed due to the complexity and cost of PAH care.
  • Recommendations focus on developing hypothesis-specific algorithms for accurate patient identification.

Conclusions:

  • Developing robust algorithms is critical for accurate PAH patient identification in administrative claims data.
  • Standardized methodologies will enhance the quality and reliability of RWE for PAH.
  • This work aims to improve the understanding of PAH treatment patterns, costs, and resource use.